Creatd, Inc. (Nasdaq CM: CRTD) (“Creatd” or the “Company”), today announced that, after testing the waters for its proposed Rights Offering, it has elected not to proceed with the offering at this time.
Galapagos Assumes Responsibility Of Late-Stage Filgotinib Trial In Crohn’s Disease
Galapagos NV (NASDAQ:GLPG) has randomized the last patient into the DIVERSITY Phase 3 study of filgotinib in the induction and maintenance…